Glucose control and variability assessed by continuous glucose monitoring in patients with type 1 diabetes and diabetic kidney disease

Fedulovs,Aleksejs; Janevica,Jana; Kruzmane,Lelde; Sokolovska,Jelizaveta

doi:10.3892/br.2024.1901

Glucose control and variability assessed by continuous glucose monitoring in patients with type 1 diabetes and diabetic kidney disease

Authors:
- Aleksejs Fedulovs
- Jana Janevica
- Lelde Kruzmane
- Jelizaveta Sokolovska
View Affiliations

Affiliations: Faculty of Medicine and Life Sciences, University of Latvia, Riga LV‑1004, Latvia
Published online on: December 2, 2024 https://doi.org/10.3892/br.2024.1901
Article Number: 23
Copyright : © Fedulovs et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Continuous glucose monitoring (CGM) has emerged as a superior method to glycated hemoglobin (HbA1c) monitoring for glycemic control assessment in type 1 diabetes (T1D). The association between CGM parameters and diabetic kidney disease (DKD) has not been extensively researched. The aim of the present study was to compare CGM metrics between patients with stable and progressive DKD and T1D. A cross‑sectional study was performed with 75 patients with T1D, of which 28 had progressive DKD, defined as an estimated glomerular filtration rate decrease of ≥3 ml/min/year or an increased albuminuria stage over the median follow‑up time of 7.46 (6.50‑8.16) years. FreeStyle Libre ProiQ Sensors were used for CGM. Insulin sensitivity was calculated according to the estimated glucose disposal rate (eGDR) formula. The results revealed that as compared with subjects with stable DKD, individuals with progressive DKD exhibited a higher average glucose level (P=0.03), spent more time above the target range (P=0.05), less time in time in range (TIR; P=0.03), had a higher median estimated HbA1c (P=0.02) and glucose management indicator (P=0.03), as well as a longer duration of hypoglycemic events (P=0.03). There were no differences in compliance levels and recognition of hypoglycemia between the DKD study groups. Differences in correlation patterns between CGM parameters in patients with stable and progressive DKD were observed. For example, glucose variability was significantly positively correlated with TIR in subjects with DKD (Ρ=0.390; P=0.04) but not in individuals without DKD. The progression of DKD was statistically significantly associated with several CGM parameters in multivariate logistic regression models. Collectively, associations between CGM metrics and DKD status were demonstrated in patients with T1D. The findings of the present study indicate the necessity for regular CGM in patients with progressive DKD for improvement of their glycemic control and DKD outcomes but also call for the development of a personalized approach to CGM data interpretation and establishing therapeutic targets in these subjects.

View Figures

View References

1	Gupta S, Dominguez M and Golestaneh L: Diabetic kidney disease: An update. Med Clin North Am. 107:689–705. 2023.PubMed/NCBI View Article : Google Scholar
2	Miller RG and Orchard TJ: Understanding metabolic memory: A tale of two studies. Diabetes. 69:291–299. 2020.PubMed/NCBI View Article : Google Scholar
3	Zhou Z, Sun B, Huang S, Zhu C and Bian M: Glycemic variability: Adverse clinical outcomes and how to improve it? Cardiovasc Diabetol. 19(102)2020.PubMed/NCBI View Article : Google Scholar
4	DeVries JH: Glucose variability: Where it is important and how to measure it. Diabetes. 62:1405–1408. 2013.PubMed/NCBI View Article : Google Scholar
5	Papachristoforou E, Lambadiari V, Maratou E and Makrilakis K: Association of glycemic indices (hyperglycemia, glucose variability, and hypoglycemia) with oxidative stress and diabetic complications. J Diabetes Res. 2020(7489795)2020.PubMed/NCBI View Article : Google Scholar
6	Wentholt IME, Kulik W, Michels RPJ, Hoekstra JBL and DeVries JH: Glucose fluctuations and activation of oxidative stress in patients with type 1 diabetes. Diabetologia. 51:183–190. 2007.PubMed/NCBI View Article : Google Scholar
7	Colomo N, López-Siguero JP, Leiva I, Fuentes N, Rubio-Martín E, Omiste A, Guerrero M, Tapia MJ, Martín-Tejedor B, Ruiz de Adana MS and Olveira G: Relationship between glucose control, glycemic variability, and oxidative stress in children with type 1 diabetes. Endocrinol Diabetes Nutr (Engl Ed). 66:540–549. 2019.PubMed/NCBI View Article : Google Scholar : (English, Spanish).
8	Dimova R, Chakarova N, Grozeva G, Kirilov G and Tankova T: The relationship between glucose variability and insulin sensitivity and oxidative stress in subjects with prediabetes. Diabetes Res Clin Pract. 158(107911)2019.PubMed/NCBI View Article : Google Scholar
9	Wadén J, Forsblom C, Thorn LM, Gordin D, Saraheimo M and Groop PH: A1C variability predicts incident cardiovascular events, microalbuminuria, and overt diabetic nephropathy in patients with type 1 diabetes. Diabetes. 58:2649–2655. 2009.PubMed/NCBI View Article : Google Scholar
10	Battelino T, Danne T, Bergenstal RM, Amiel SA, Beck R, Biester T, Bosi E, Buckingham BA, Cefalu WT, Close KL, et al: Clinical targets for continuous glucose monitoring data interpretation: Recommendations from the international consensus on time in range. Diabetes Care. 42:1593–1603. 2019.PubMed/NCBI View Article : Google Scholar
11	Purandare VB, Bale C, Kakrani A and Unnikrishnan AG: Understanding glycemic variability. J Diabetology. 12:275–284. 2021.
12	Lachin JM, Bebu I, Bergenstal RM, Pop-Busui R, Service FJ, Zinman B and Nathan DM: Association of glycemic variability in type 1 diabetes with progression of microvascular outcomes in the diabetes control and complications trial. Diabetes Care. 40:777–783. 2017.PubMed/NCBI View Article : Google Scholar
13	Ling J, Ng JKC, Chan JCN and Chow E: Use of continuous glucose monitoring in the assessment and management of patients with diabetes and chronic kidney disease. Front Endocrinol (Lausanne). 13(869899)2022.PubMed/NCBI View Article : Google Scholar
14	Bomholt T, Rix M, Almdal T, Knop FK, Rosthøj S, Jørgensen MB, Feldt-Rasmussen B and Hornum M: Glucose variability in maintenance hemodialysis patients with type 2 diabetes: Comparison of dialysis and nondialysis days. Hemodial Int. 27:126–133. 2023.PubMed/NCBI View Article : Google Scholar
15	Bushljetik IR, Trajceska L, Pusevski V and Spasovski G: Glucose levels during dialysis with glucose-free versus glucose-rich dialysate fluid. Prilozi. 40:41–46. 2019.PubMed/NCBI View Article : Google Scholar
16	El Malahi A, Van Elsen M, Charleer S, Dirinck E, Ledeganck K, Keymeulen B, Crenier L, Radermecker R, Taes Y, Vercammen C, et al: Relationship between time in range, glycemic variability, HbA1c, and complications in adults with type 1 diabetes mellitus. J Clin Endocrinol Metab. 107:e570–e581. 2022.PubMed/NCBI View Article : Google Scholar
17	Kovatchev B: Glycemic variability: Risk factors, assessment, and control. J Diabetes Sci Technol. 13:627–635. 2019.PubMed/NCBI View Article : Google Scholar
18	Galindo RJ, Beck RW, Scioscia MF, Umpierrez GE and Tuttle KR: Glycemic monitoring and management in advanced chronic kidney disease. Endocr Rev. 41:756–774. 2020.PubMed/NCBI View Article : Google Scholar
19	Ahola AJ, Radzeviciene L, Zaharenko L, Bulum T, Skrebinska S, Prakapiene E, Blaslov K, Roso V, Rovite V, Pirags V, et al: Association between symptoms of depression, diabetes complications and vascular risk factors in four European cohorts of individuals with type 1 diabetes-InterDiane Consortium. Diabetes Res Clin Pract. 170(108495)2020.PubMed/NCBI View Article : Google Scholar
20	Zamora-Ros R, Biessy C, Rothwell JA, Monge A, Lajous M, Scalbert A, López-Ridaura R and Romieu I: Dietary polyphenol intake and their major food sources in the Mexican Teachers' Cohort. Br J Nutr. 120:353–360. 2018.PubMed/NCBI View Article : Google Scholar
21	Sokolovska J, Dekante A, Baumane L, Pahirko L, Valeinis J, Dislere K, Rovite V, Pirags V and Sjakste N: Nitric oxide metabolism is impaired by type 1 diabetes and diabetic nephropathy. Biomed Rep. 12:251–258. 2020.PubMed/NCBI View Article : Google Scholar
22	American Diabetes Association Professional Practice Committee. 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2024. Diabetes Care. 47 (Suppl 1):S219–S230. 2024.PubMed/NCBI View Article : Google Scholar
23	Colombo M, Valo E, McGurnaghan SJ, Sandholm N, Blackbourn LAK, Dalton RN, Dunger D, Groop PH, McKeigue PM, Forsblom C, et al: Biomarker panels associated with progression of renal disease in type 1 diabetes. Diabetologia. 62:1616–1627. 2019.PubMed/NCBI View Article : Google Scholar
24	Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF III, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, et al: A new equation to estimate glomerular filtration rate. Ann Intern Med. 150(604)2009.PubMed/NCBI View Article : Google Scholar
25	Wadén J, Tikkanen H, Forsblom C, Fagerudd J, Pettersson-Fernholm K, Lakka T, Riska M and Groop PH: FinnDiane Study Group. Leisure time physical activity is associated with poor glycemic control in type 1 diabetic women. Diabetes Care. 28:777–782. 2005.PubMed/NCBI View Article : Google Scholar
26	R Core Team: A language and environment for statistical computing, 2023.
27	Wickham H: ggplot2: Create Elegant Data Visualisations Using the Grammar of Graphics, 2024.
28	Griggs S and Morris NS: Fatigue among adults with type 1 diabetes mellitus and implications for self-management: An integrative review. Diabetes Educ. 44:325–339. 2018.PubMed/NCBI View Article : Google Scholar
29	Fedulovs A, Tzivian L, Zalizko P, Ivanova S, Bumane R, Janeviča J, Krūzmane L, Krustins E and Sokolovska J: Progression of diabetic kidney disease and gastrointestinal symptoms in patients with type I diabetes. Biomedicines. 11(2679)2023.PubMed/NCBI View Article : Google Scholar
30	Williams S, Raheim SA, Khan MI, Rubab U, Kanagala P, Zhao SS, Marshall A, Brown E and Alam U: Cardiac autonomic neuropathy in type 1 and 2 diabetes: Epidemiology, pathophysiology, and management. Clin Ther. 44:1394–1416. 2022.PubMed/NCBI View Article : Google Scholar
31	Yun JS, Park YM, Han K, Kim HW, Cha SA, Ahn YB and Ko SH: Severe hypoglycemia and the risk of end stage renal disease in type 2 diabetes. Sci Rep. 11(4305)2021.PubMed/NCBI View Article : Google Scholar
32	Sagmeister MS, Harper L and Hardy RS: Cortisol excess in chronic kidney disease-A review of changes and impact on mortality. Front Endocrinol (Lausanne). 13(1075809)2023.PubMed/NCBI View Article : Google Scholar
33	Hamilton A, Zhang Q, Salehi A, Willems M, Knudsen JG, Ringgaard AK, Chapman CE, Gonzalez-Alvarez A, Surdo NC, Zaccolo M, et al: Adrenaline stimulates glucagon secretion by Tpc2-dependent Ca2+ mobilization from acidic stores in pancreatic α-cells. Diabetes. 67:1128–1139. 2018.PubMed/NCBI View Article : Google Scholar
34	Ceriello A, Esposito K, Piconi L, Ihnat MA, Thorpe JE, Testa R, Boemi M and Giugliano D: Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes. 57:1349–1354. 2008.PubMed/NCBI View Article : Google Scholar
35	Costantino S, Paneni F, Battista R, Castello L, Capretti G, Chiandotto S, Tanese L, Russo G, Pitocco D, Lanza GA, et al: Impact of glycemic variability on chromatin remodeling, oxidative stress, and endothelial dysfunction in patients with type 2 diabetes and with target HbA1c levels. Diabetes. 66:2472–2482. 2017.PubMed/NCBI View Article : Google Scholar
36	Yapanis M, James S, Craig ME, O'Neal D and Ekinci EI: Complications of diabetes and metrics of glycemic management derived from continuous glucose monitoring. J Clin Endocrinol Metab. 107:e2221–e2236. 2022.PubMed/NCBI View Article : Google Scholar
37	Šoupal J, Škrha J, Fajmon M, Horová E, Mráz M, Škrha J and Prázný M: Glycemic variability is higher in type 1 diabetes patients with microvascular complications irrespective of glycemic control. Diabetes Technol Ther. 16:198–203. 2014.PubMed/NCBI View Article : Google Scholar
38	Gheith O, Farouk N, Nampoory N, Halim MA and Al-Otaibi T: Diabetic kidney disease: World wide difference of prevalence and risk factors. J Nephropharmacol. 5:49–56. 2016.PubMed/NCBI
39	Ohta M, Babazono T, Uchigata Y and Iwamoto Y: Comparison of the prevalence of chronic kidney disease in Japanese patients with Type 1 and Type 2 diabetes. Diabetic Medicine. 27:1017–1023. 2010.PubMed/NCBI View Article : Google Scholar
40	Marshall SM: Natural history and clinical characteristics of CKD in Type 1 and Type 2 diabetes mellitus. Adv Chronic Kidney Dis. 21:267–272. 2014.PubMed/NCBI View Article : Google Scholar
41	Bergenstal RM: Glycemic variability and diabetes complications: Does it matter? Simply put, there are better glycemic markers! Diabetes Care. 38:1615–1621. 2015.PubMed/NCBI View Article : Google Scholar
42	Habte-Asres HH, Wheeler DC and Forbes A: The association between glycaemic variability and progression of chronic kidney disease: A Systematic Review. Compr Clin Med. 4(102)2022.
43	Jansson Sigfrids F, Lithovius R, Groop P and Thorn LM: Lessons learned from the FinnDiane Study: Epidemiology and metabolic risk factors for diabetic kidney disease in type 1 diabetes. Diabet Med. (e15431)2024.PubMed/NCBI View Article : Google Scholar : doi: 10.1111/dme.15431 (Epub ahead of print).
44	Targher G, Mantovani A, Pichiri I, Mingolla L, Cavalieri V, Mantovani W, Pancheri S, Trombetta M, Zoppini G, Chonchol M, et al: Nonalcoholic fatty liver disease is independently associated with an increased incidence of chronic kidney disease in patients with type 1 diabetes. Diabetes Care. 37:1729–1736. 2014.PubMed/NCBI View Article : Google Scholar
45	Clinck I, Mertens J, Wouters K, Dirinck E and De Block C: Insulin resistance and CGM-Derived parameters in people with type 1 diabetes: Are they associated? J Clin Endocrinol Metab. 109:e2131–e2140. 2024.PubMed/NCBI View Article : Google Scholar
46	Grube D, Wei G, Boucher R, Abraham N, Zhou N, Gonce V, Carle J, Simmons DL and Beddhu S: Insulin use in chronic kidney disease and the risk of hypoglycemic events. BMC Nephrol. 23(73)2022.PubMed/NCBI View Article : Google Scholar
47	Amiel SA: The consequences of hypoglycaemia. Diabetologia. 64:963–970. 2021.PubMed/NCBI View Article : Google Scholar
48	Bumbu A, Moutairou A, Matar O, Fumeron F, Velho G, Riveline JP, Gautier JF, Marre M, Roussel R and Potier L: Non-severe hypoglycaemia is associated with weight gain in patients with type 1 diabetes: Results from the Diabetes Control and Complication Trial. Diabetes Obes Metab. 20:1289–1292. 2018.PubMed/NCBI View Article : Google Scholar
49	Jakubowska Z and Malyszko J: Continuous glucose monitoring in people with diabetes and end-stage kidney disease-review of association studies and Evidence-Based discussion. J Nephrol. 37:267–279. 2023.PubMed/NCBI View Article : Google Scholar
50	van Duinkerken E, Snoek FJ and de Wit M: The cognitive and psychological effects of living with type 1 diabetes: A narrative review. Diabet Med. 37:555–563. 2020.PubMed/NCBI View Article : Google Scholar
51	Szadkowska A, Czyżewska K, Pietrzak I, Mianowska B, Jarosz-Chobot P and Myśliwiec M: Hypoglycaemia unawareness in patients with type 1 diabetes. Pediatr Endocrinol Diabetes Metab. 24:126–134. 2018.PubMed/NCBI View Article : Google Scholar
52	Vloemans AF, van Beers CAJ, de Wit M, Cleijne W, Rondags SM, Geelhoed-Duijvestijn PH, Kramer MHH, Serné EH and Snoek FJ: Keeping safe. Continuous glucose monitoring (CGM) in persons with Type 1 diabetes and impaired awareness of hypoglycaemia: A qualitative study. Diabet Med. 34:1470–1476. 2017.PubMed/NCBI View Article : Google Scholar
53	Friedman JG, Cardona Matos Z, Szmuilowicz ED and Aleppo G: Use of continuous glucose monitors to manage type 1 diabetes mellitus: Progress, challenges, and recommendations. Pharmgenomics Pers Med. 16:263–276. 2023.PubMed/NCBI View Article : Google Scholar
54	Rickels MR, Peleckis AJ, Dalton-Bakes C, Naji JR, Ran NA, Nguyen HL, O'Brien S, Chen S, Lee I and Schutta MH: Continuous glucose monitoring for hypoglycemia avoidance and glucose counterregulation in long-standing type 1 diabetes. J Clin Endocrinol Metab. 103:105–114. 2018.PubMed/NCBI View Article : Google Scholar
55	Choudhary P, Ramasamy S, Green L, Gallen G, Pender S, Brackenridge A, Amiel SA and Pickup JC: Real-time continuous glucose monitoring significantly reduces severe hypoglycemia in hypoglycemia-unaware patients with type 1 diabetes. Diabetes Care. 36:4160–4162. 2013.PubMed/NCBI View Article : Google Scholar